Home
Business News
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Related Posts
Please leave this field emptyGet every new post delivered right to your inbox. Email * Check your inbox or spam…
Duke Energy Foundation has awarded the Richland Volunteer Fire Department a $12,000 Duke Energy Sustainable Solutions grant to help the…
TARRYTOWN, N.Y. and WASHINGTON , Jan. 20, 2022 /PRNewswire/ — Over $3 Million to be Awarded in Oldest and…
Please leave this field emptyGet every new post delivered right to your inbox. Email * Check your inbox or spam…
Software reduces harmful emissions and fuel consumption with Artificial Intelligence /Machine Learning enabled continuous tuning for gas turbines Lower total…
Team-based health care group that serves Medicare patients from a wide range of health plans to open 26 new centers…
Feb. 3 at 4:30 p.m. EST IRVINE, Calif. –(BUSINESS WIRE)–Jan. 20, 2022– Skyworks Solutions, Inc. (Nasdaq: SWKS), an innovator of…
Spruce addresses significant unmet needs around spending, saving, and planning KANSAS CITY, Mo., Jan. 20, 2022 (GLOBE NEWSWIRE) — Living…
Please leave this field emptyGet every new post delivered right to your inbox. Email * Check your inbox or spam…
Company Added a Record 86,000 Gross Rooms and 517 Properties in 2021, Achieving Net Rooms Growth of Approximately 4 Percent…